EP1539809A4 - Hcv-fusionsproteine mit modifizierten ns3-domänen - Google Patents

Hcv-fusionsproteine mit modifizierten ns3-domänen

Info

Publication number
EP1539809A4
EP1539809A4 EP03763172A EP03763172A EP1539809A4 EP 1539809 A4 EP1539809 A4 EP 1539809A4 EP 03763172 A EP03763172 A EP 03763172A EP 03763172 A EP03763172 A EP 03763172A EP 1539809 A4 EP1539809 A4 EP 1539809A4
Authority
EP
European Patent Office
Prior art keywords
domains
modified
fusion proteins
hcv fusion
hcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03763172A
Other languages
English (en)
French (fr)
Other versions
EP1539809A2 (de
Inventor
Michael Houghton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of EP1539809A2 publication Critical patent/EP1539809A2/de
Publication of EP1539809A4 publication Critical patent/EP1539809A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP03763172A 2002-07-02 2003-07-02 Hcv-fusionsproteine mit modifizierten ns3-domänen Withdrawn EP1539809A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39369402P 2002-07-02 2002-07-02
US393694P 2002-07-02
US39451002P 2002-07-08 2002-07-08
US394510P 2002-07-08
PCT/US2003/020996 WO2004005473A2 (en) 2002-07-02 2003-07-02 Hcv fusion proteins with modified ns3 domains

Publications (2)

Publication Number Publication Date
EP1539809A2 EP1539809A2 (de) 2005-06-15
EP1539809A4 true EP1539809A4 (de) 2006-03-08

Family

ID=30118384

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03763172A Withdrawn EP1539809A4 (de) 2002-07-02 2003-07-02 Hcv-fusionsproteine mit modifizierten ns3-domänen

Country Status (8)

Country Link
EP (1) EP1539809A4 (de)
JP (2) JP2005532064A (de)
CN (1) CN1678630A (de)
AU (1) AU2003248818A1 (de)
CA (1) CA2491508A1 (de)
PL (1) PL374349A1 (de)
RU (1) RU2005102484A (de)
WO (1) WO2004005473A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491808B2 (en) * 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
WO2004039950A2 (en) * 2002-10-25 2004-05-13 Chiron Corporation Activation of hcv-specific cells
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
RU2006144714A (ru) * 2004-05-17 2008-06-27 Чирон Корпорейшн (Us) Усеченный ns5 домен вируса гепатита с и содержащие его слитые белки
ES2377978T3 (es) * 2004-08-27 2012-04-03 Novartis Vaccines And Diagnostics, Inc. Mutantes de proteínas no estructurales de VHC y usos de los mismos
AU2011254055B2 (en) * 2004-10-18 2012-12-20 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
AU2005295317B2 (en) * 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
EP1888751A2 (de) * 2005-05-25 2008-02-20 Tripep Ab Nichtstrukturelles ns3/4a-fusionsgen des hepatitis-c-virus
WO2007041861A1 (en) * 2005-10-13 2007-04-19 Virexx Medical Corp. Chimeric antigen containing hepatitis c virus polypeptide and fc fragment for eliciting an immune response
GB0524408D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2061888A2 (de) * 2006-08-25 2009-05-27 Novartis AG Hcv-fusionspolypeptide
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
US9321847B2 (en) 2010-09-20 2016-04-26 Ramot At Tel Aviv University Ltd. Activatable toxin complexes comprising a cleavable inhibitory peptide
CN107735499B (zh) * 2015-03-27 2022-05-03 奥索临床诊断有限公司 Hcv ns4a/经修饰的ns3多肽及其用途
CN106749672B (zh) * 2016-11-18 2020-06-30 江西农业大学 一种丙型肝炎病毒融合抗原蛋白及其应用
CN111153963B (zh) * 2020-01-19 2021-08-10 华南理工大学 抗炎五肽及其提取分离方法和在改善记忆中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012677A2 (en) * 1993-11-04 1995-05-11 Innogenetics N.V. Immunodominant human t-cell epitopes of hepatitis c virus
WO2001038360A2 (en) * 1999-11-24 2001-05-31 Chiron Corporation Novel hcv non-structural polypeptide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090812A1 (en) * 2000-05-23 2001-11-29 Massachusetts Institute Of Technology Ultraviolet fluoride nonlinear devices

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012677A2 (en) * 1993-11-04 1995-05-11 Innogenetics N.V. Immunodominant human t-cell epitopes of hepatitis c virus
WO2001038360A2 (en) * 1999-11-24 2001-05-31 Chiron Corporation Novel hcv non-structural polypeptide

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COOPER S ET AL: "Analysis of a successful immune response against hepatitis C virus.", IMMUNITY. APR 1999, vol. 10, no. 4, April 1999 (1999-04-01), pages 439 - 449, XP002359338, ISSN: 1074-7613 *
HIJIKATA M ET AL: "TWO DISTINCT PROTEINASE ACTIVITIES REQUIRED FOR THE PROCESSING OF A PUTATIVE NONSTRUCTAL PRECURSOR PROTEIN OF HEPATITIS C VIRUS", JOURNAL OF VIROLOGY, NEW YORK, US, US, vol. 67, no. 8, August 1993 (1993-08-01), pages 4665 - 4675, XP001041543, ISSN: 0022-538X *
LOVE R A ET AL: "The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site.", CELL. 18 OCT 1996, vol. 87, no. 2, 18 October 1996 (1996-10-18), pages 331 - 342, XP002359935, ISSN: 0092-8674 *
ZEMEL R ET AL: "Mutations at vicinity of catalytic sites of hepatitis C virus NS3 serine protease gene isolated from hepatocellular carcinoma tissue.", DIGESTIVE DISEASES AND SCIENCES. NOV 2000, vol. 45, no. 11, November 2000 (2000-11-01), pages 2199 - 2202, XP002359947, ISSN: 0163-2116 *

Also Published As

Publication number Publication date
CA2491508A1 (en) 2004-01-15
JP2006265267A (ja) 2006-10-05
WO2004005473A2 (en) 2004-01-15
PL374349A1 (en) 2005-10-17
JP2005532064A (ja) 2005-10-27
WO2004005473A3 (en) 2004-04-01
CN1678630A (zh) 2005-10-05
RU2005102484A (ru) 2006-01-20
AU2003248818A1 (en) 2004-01-23
EP1539809A2 (de) 2005-06-15

Similar Documents

Publication Publication Date Title
IL166751A0 (en) Modified transferin-antibody fusion proteins
PL374349A1 (en) Hcv fusion proteins with modified ns3 domains
IL166750A0 (en) Modified transferrin fusion proteins
AU2003239365A8 (en) Recombinant glycosyltransferase fusion proteins
EP1663278A4 (de) Epo mimetika-peptide und fusionsproteine
IL171800A (en) Ns5b hcv inhibitors and methods based on these inhibitors
EP1594530A4 (de) Albuminfusionsproteine
AU2003279766A8 (en) Microfluidic protein crystallography
PL366621A1 (en) Core-glycosylated hcv envelope proteins
GB0209884D0 (en) Proteins
GB0315248D0 (en) HCV regulated protein expression
GB0220770D0 (en) Proteins
GB0200689D0 (en) Fusion proteins
EP1824978A4 (de) Hcv-f-protein und verwendungen davon
EP1487874A4 (de) Falp-proteine
GB0212067D0 (en) Proteins
GB0314456D0 (en) Interferon gamma-like protein
AU2003270055A8 (en) Neurotransmission-associated proteins
GB0323897D0 (en) Coloured fusion proteins
AU2003300785A8 (en) Carbohydrate-associated proteins
GB0211903D0 (en) Proteins
AU2003236908A8 (en) Proteins
AU2003295760A8 (en) Organelle-associated proteins
GB0216757D0 (en) Proteins
GB0102678D0 (en) Combinatorial protein domains

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050124

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20060119

17Q First examination report despatched

Effective date: 20061204

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070417